Roche launches new Cedex Bio HT Analyzer for cell fermentation process analytics
Penzberg, Germany, 29 October 2012
New instrument completes portfolio for customers with high-throughput applications
Today Roche announced the global launch of its Cedex Bio HT Analyzer for the highly reliable determination of metabolites and substrates in mammalian and microbial cell fermentation. The Cedex Bio HT System offers very precise analytics, a broad test portfolio allowing flexible adaption of additional test menus as well as very good convenience thanks to a highly automated platform processing up to 120 tests per hour.
Designed for high-throughput applications such as in-process development, its data can be directly compared with data produced by Cedex Bio and Cedex Bio HT Analyzers located worldwide, making these instruments ideal for high scale manufacturing in a global biotech production network. Furthermore, customers benefit from Roche's established global technical service and application support network.
“The Cedex Bio HT Analyzer sets a new gold standard in bioprocess analytics. Its precise test results and high data consistency help to create optimal conditions for fermentation processes, which in turn result in high product quality and yield.” said Ruedi Stoffel, Head of Custom Biotech at Roche. “The Cedex Bio HT Analyzer is able to deliver the high data precision and reproducibility for critical process parameters that are essential to the successful implementation of authority’s regulations in biopharmaceutical production. As a result, one of our early customers entirely switched to the Cedex Bio and new Cedex Bio HT Analyzers in their biomanufacturing network”
By minimizing hands-on-time, the Cedex Bio HT Analyzer demonstrates greater precision, sensitivity and linearity than instruments that use membrane-based technology. It includes three different measuring methods enabling the analysis of IgG (immunoglobulin G) in addition to LDH (lactate dehydrogenase) and various substrates and metabolites as glutamate, glutamine, sodium, potassium, glucose, lactate and ammonia.
About the Cedex product family
Roche now supplies reliable systems for all types of in-process control of fermentation processes using mammalian and microbial cells in the form of its Cedex Bio Analyzer for low-throughput and its new Cedex Bio HT Analyzer for high-throughput applications. To obtain even more comprehensive in-process manufacturing information, Roche recommends combining its Cedex Bio instruments with its Cedex HiRes Cell Analyzers.
CEDEX is a trademark of Roche.
For use in quality control/manufacturing processes only.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
All trademarks used or mentioned in this release are protected by law.